Soricap 2525mg
Type:7 Capsules
Generic Name:Acitretin
Manufacturer:Unimed Unihealth Pharmaceuticals Ltd.
Price:৳595.00
Indication
Oral Darier's disease Adult: Initially, 10 mg daily for 2-4 wk. Max: 50 mg/day. Congenital icthyosis Adult: Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods. Severe psoriasis Adult: Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods. Severe lichen planus Adult: Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods.
Administration
Concomitant use with keratolytics or high dose vitamin A. Reduces anticoagulant effect of coumarins e.g. warfarin. Concomitant use of microdised progestin oral contraceptives. Concomitant use of methotrexate can potentiate hepatotoxicty. Concomitant use with tetracycline.
Adult Dose
Female patients to avoid alcohol during and 2 mth after treatment. Avoid blood donation during therapy or at least 1-3 yr after stopping therapy. Children. Radiographic treatment for prolonged therapy. Therapy should not last >6 mth. Monitor plasma lipid and glucose levels (especially diabetics) regularly. Monitor LFTs. Lactation: enters breast milk/not recommended.
Renal Dose
Acitretin is an active metabolite of etretinate but its mechanism of action is unknown.
Mode of Action
Should be taken with food. Take w/ main meals or w/ a glass of milk.
Precaution
Lichen planus, Psoriasis, Congenital icthyosis, Darier's disease
Pregnancy Category Note
Cheilitis (>75%),Alopecia (50-75%),Hypertriglyceridemia (50-75%),Skin peeling (50-75%),Dry skin (25-50%),Dysglycemia (25-50%),Increased LFT (25-50%),Nail disorder (25-50%),Pruritus (25-50%),Rhinitis (25-50%),Arthralgia (10-25%),Changes in phosphorus, potassium, sodium, & magnesium levels (10-25%),Dry mouth (10-25%),Epistaxis (10-25%),Erythematous rash (10-25%),Hepatotoxicity (10-25%),Hyperesthesia (10-25%),Paresthesia (10-25%),Paronychia (10-25%),Rigors (10-25%),Skin atrophy (10-25%),Spinal hyperostosis (10-25%),Sticky skin (10-25%),Xerophthalmia (10-25%) 1-10% Edema,Flushing,Depression,Fatigue,Headache,Insomnia,Somnolence,Abdominal pain,Anorexia,Diarrhea,Gingivitis,Increased appetite,Nausea,Stomatitis,Vomiting,Hot flashes,Vision changes,Corneal epithelial abnormality,Sinusitis Potentially Fatal: Phototoxicity, jaundice, hepatitis and hepatotoxity.
Interaction
Pregnancy (before the start, during and at least 2-3 yr after cessation of therapy), lactation. Hepatic and renal impairment. Hyperlipidaemia.
